Arnold C. Hanish
CIK: 0001233253
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Aug 31, 2026DCOY
Decoy Therapeutics Inc.
Award(A)Direct3K shares- - Aug 27, 2026OMER
OMEROS CORP
Exercise(M)Direct2.5K shares at avg. $15.81$40K - Aug 27, 2026OMER
OMEROS CORP
Exercise(M)Direct7.5K shares at avg. $14.66$110K - Aug 27, 2026OMER
OMEROS CORP
Sale(S)Direct5K shares at avg. $19.02$95K - Aug 27, 2026OMER
OMEROS CORP
Sale(S)Direct5K shares at avg. $18.88$94K - Aug 26, 2026OMER
OMEROS CORP
Exercise(M)Direct5K shares at avg. $15.81$79K - Aug 26, 2026OMER
OMEROS CORP
Sale(S)Direct5K shares at avg. $18.53$93K - Jun 18, 2026OMER
OMEROS CORP
Award(A)DirectStock Option (Right to Buy)
15K shares- - Dec 30, 2025SLRX
Salarius Pharmaceuticals, Inc.
Sale(S)Direct12 shares at avg. $0.64$7.676 - Dec 30, 2025SLRX
Salarius Pharmaceuticals, Inc.
Sale(S)Indirect15 shares at avg. $0.64$9.596 - Nov 20, 2025SLRX
Salarius Pharmaceuticals, Inc.
Purchase(P)Indirect5K shares at avg. $0.75$4K - Jun 27, 2025OMER
OMEROS CORP
Award(A)DirectStock Option (Right to Buy)
15K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 31, 2026 |  DCOY Decoy Therapeutics Inc. | Award(A) | 3,000 | - | $0 | Direct |
| Aug 27, 2026 |  OMER OMEROS CORP | Exercise(M) | 2,500 | $15.81 | $39,525 | Direct |
| Aug 27, 2026 | OMER OMEROS CORP | Exercise(M) | 7,500 | $14.66 | $109,950 | Direct |
| Aug 27, 2026 | OMER OMEROS CORP | Sale(S) | 5,000 | $19.02 | $95,081 | Direct |
| Aug 27, 2026 | OMER OMEROS CORP | Sale(S) | 5,000 | $18.88 | $94,381 | Direct |
| Aug 26, 2026 | OMER OMEROS CORP | Exercise(M) | 5,000 | $15.81 | $79,050 | Direct |
| Aug 26, 2026 | OMER OMEROS CORP | Sale(S) | 5,000 | $18.53 | $92,633 | Direct |
| Jun 18, 2026 | OMER OMEROS CORP | Award(A) Stock Option (Right to Buy) | 15,000 | - | - | Direct |
| Dec 30, 2025 |  SLRX Salarius Pharmaceuticals, Inc. | Sale(S) | 12 | $0.64 | $8 | Direct |
| Dec 30, 2025 | SLRX Salarius Pharmaceuticals, Inc. | Sale(S) | 15 | $0.64 | $10 | Indirect |
| Nov 20, 2025 | SLRX Salarius Pharmaceuticals, Inc. | Purchase(P) | 5,000 | $0.75 | $3,741 | Indirect |
| Jun 27, 2025 | OMER OMEROS CORP | Award(A) Stock Option (Right to Buy) | 15,000 | - | - | Direct |
1-12 of 12 transactions
About HANISH ARNOLD C
HANISH ARNOLD C (SEC CIK 0001233253) files insider reports with the SEC as Director of Decoy Therapeutics Inc. (DCOY) and Director of OMEROS CORP (OMER).
Signal8 holds 6 ownership filings by HANISH ARNOLD C, all Form 4s, filed between Jul 1, 2025 and Sep 2, 2026. Those filings report 12 transactions, from Jun 27, 2025 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on HANISH ARNOLD C's filings is in HOUSTON, TX.
Recent filings by HANISH ARNOLD C
- Aug 31, 2026: Grant or award of DCOY shares (Form 4, code A).
- Aug 27, 2026: Option exercises of OMER shares (2 lines, Form 4, code M).
- Aug 27, 2026: Open-market sales of OMER shares (2 lines, Form 4, code S).
- Aug 26, 2026: Option exercise of OMER shares (Form 4, code M).
- Aug 26, 2026: Open-market sale of OMER shares (Form 4, code S).
Other insiders filing for Decoy Therapeutics Inc. (DCOY)
- Lieber Jonathan I, Director
- PIERCE FREDERICK II, Chief Executive Officer
- Marschel Peter Klaus, Chief Business Officer
- Rosenblum Mark J, Chief Financial Officer
- Hibner Barbara Louise, Chief Scientific Officer
- Lammers Paul, Director